{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:04:56Z","timestamp":1787580296951,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-07113-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:45:41Z","timestamp":1751373941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Huaning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianmei","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"12","key":"7113_CR1","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M, et al. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the global burden of disease (GBD) 2019. Mol Psychiatry. 2023;28(12):5319\u201327.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"7113_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195\u2013203.","journal-title":"Schizophr Bull"},{"key":"7113_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-244X-12-150","volume":"12","author":"L Clemmensen","year":"2012","unstructured":"Clemmensen L, Vernal DL, Steinhausen HC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012;12:150.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"7113_CR4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1192\/bjp.bp.108.060723","volume":"195","author":"TK Rajji","year":"2009","unstructured":"Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry. 2009;195(4):286\u201393.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"7113_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.chc.2012.07.011","volume":"21","author":"AE Maloney","year":"2012","unstructured":"Maloney AE, Yakutis LJ, Frazier JA. Empirical evidence for psychopharmacologic treatment in early-onset psychosis and schizophrenia. Child Adolesc Psychiatric Clin. 2012;21(4):885\u2013909.","journal-title":"Child Adolesc Psychiatric Clin"},{"issue":"8","key":"7113_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/chi.0b013e31807083fd","volume":"46","author":"JA Frazier","year":"2007","unstructured":"Frazier JA, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2007;46(8):979\u201388.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"7113_CR7","first-page":"e39488","volume":"15","author":"N Gupta","year":"2023","unstructured":"Gupta N, Gupta M, Esang M. Lost in translation: challenges in the diagnosis and treatment of Early-Onset schizophrenia. Cureus. 2023;15(5):e39488.","journal-title":"Cureus"},{"key":"7113_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.schres.2023.05.015","volume":"257","author":"Y Yin","year":"2023","unstructured":"Yin Y, et al. Short-term antipsychotic treatment response in early-onset, typical-onset, and late-onset first episode schizophrenia. Schizophr Res. 2023;257:58\u201363.","journal-title":"Schizophr Res"},{"issue":"1","key":"7113_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2009","unstructured":"Buchanan RW, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2009;36(1):71\u201393.","journal-title":"Schizophr Bull"},{"issue":"9","key":"7113_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372.","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"7113_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.schres.2013.08.001","volume":"152","author":"RB Zipursky","year":"2014","unstructured":"Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152(2\u20133):408\u201314.","journal-title":"Schizophr Res"},{"issue":"10","key":"7113_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.euroneuro.2015.06.009","volume":"25","author":"AM Persico","year":"2015","unstructured":"Persico AM, et al. Unmet needs in paediatric psychopharmacology: present scenario and future perspectives. Eur Neuropsychopharmacol. 2015;25(10):1513\u201331.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"7113_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1055\/a-1854-0185","volume":"55","author":"JD Lopez-Morinigo","year":"2022","unstructured":"Lopez-Morinigo JD, Leucht S, Arango C. Pharmacological treatment of Early-Onset schizophrenia: A critical review, Evidence-Based clinical guidance and unmet needs. Pharmacopsychiatry. 2022;55(5):233\u201345.","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 2","key":"7113_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4103\/psychiatry.IndianJPsychiatry_556_18","volume":"61","author":"S Grover","year":"2019","unstructured":"Grover S, Avasthi A. Clinical practice guidelines for the management of schizophrenia in children and adolescents. Indian J Psychiatry. 2019;61(Suppl 2):277\u201393.","journal-title":"Indian J Psychiatry"},{"issue":"9","key":"7113_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/0706743717720197","volume":"62","author":"S Abidi","year":"2017","unstructured":"Abidi S, et al. Canadian guidelines for the Pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth. Can J Psychiatry. 2017;62(9):635\u201347.","journal-title":"Can J Psychiatry"},{"key":"7113_CR16","doi-asserted-by":"publisher","first-page":"844098","DOI":"10.3389\/fpsyt.2022.844098","volume":"13","author":"A Vita","year":"2022","unstructured":"Vita A, et al. Patterns of care for adolescent with schizophrenia: A Delphi-Based consensus study. Front Psychiatry. 2022;13:844098.","journal-title":"Front Psychiatry"},{"issue":"5","key":"7113_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JCP.0000000000000559","volume":"36","author":"JV Brauner","year":"2016","unstructured":"Brauner JV, et al. Off-Label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol. 2016;36(5):500\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"7113_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2215-0366(18)30511-X","volume":"6","author":"Y Huang","year":"2019","unstructured":"Huang Y, et al. Prevalence of mental disorders in china: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211\u201324.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"7113_CR19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1186\/s12888-023-05247-0","volume":"23","author":"YH Yu","year":"2023","unstructured":"Yu YH, Lu Q. Prevalence, risk factors and multiple outcomes of treatment delay in Chinese patients with schizophrenia. BMC Psychiatry. 2023;23(1):748.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"7113_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12888-020-02962-w","volume":"21","author":"J Zhang","year":"2021","unstructured":"Zhang J, et al. Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in china: a retrospective study. BMC Psychiatry. 2021;21(1):10.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"7113_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00787-018-1242-9","volume":"28","author":"CW Hsu","year":"2019","unstructured":"Hsu CW, Lee SY, Wang LJ. Gender differences in the prevalence, comorbidities and antipsychotic prescription of early-onset schizophrenia: a nationwide population-based study in Taiwan. Eur Child Adolesc Psychiatry. 2019;28(6):759\u201367.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"12","key":"7113_CR22","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1177\/0004867418805559","volume":"52","author":"H Qiu","year":"2018","unstructured":"Qiu H, et al. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan. Aust N Z J Psychiatry. 2018;52(12):1202\u201312.","journal-title":"Aust N Z J Psychiatry"},{"key":"7113_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jad.2022.02.054","volume":"305","author":"H Wang","year":"2022","unstructured":"Wang H, et al. One-year incidence rate of treatment resistant depression (TRD) and treatment characteristics in China. J Affect Disord. 2022;305:77\u201384.","journal-title":"J Affect Disord"},{"issue":"1","key":"7113_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41537-020-00122-3","volume":"6","author":"S Oh","year":"2020","unstructured":"Oh S, et al. Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital. NPJ Schizophr. 2020;6(1):32.","journal-title":"NPJ Schizophr"},{"issue":"10","key":"7113_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00787-014-0668-y","volume":"24","author":"H Verdoux","year":"2015","unstructured":"Verdoux H, et al. Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013. Eur Child Adolesc Psychiatry. 2015;24(10):1181\u201391.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"7113_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-244X-6-8","volume":"6","author":"H Ascher-Svanum","year":"2006","unstructured":"Ascher-Svanum H, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6:8.","journal-title":"BMC Psychiatry"},{"key":"7113_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-244X-5-26","volume":"5","author":"D Faries","year":"2005","unstructured":"Faries D, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005;5:26.","journal-title":"BMC Psychiatry"},{"key":"7113_CR28","unstructured":"Organization WH. The ATC\/DDD Methodology. [cited 2024 May 9]; Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/methodology"},{"issue":"2","key":"7113_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jsps.2013.03.003","volume":"22","author":"WM Sweileh","year":"2014","unstructured":"Sweileh WM, et al. Evaluation of defined daily dose, percentage of British National formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization. Saudi Pharm J. 2014;22(2):127\u201332.","journal-title":"Saudi Pharm J"},{"issue":"4","key":"7113_CR30","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/schbul\/sbp149","volume":"37","author":"H Uchida","year":"2011","unstructured":"Uchida H, et al. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull. 2011;37(4):788\u201399.","journal-title":"Schizophr Bull"},{"issue":"1","key":"7113_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13034-024-00766-4","volume":"18","author":"W Zhaojian","year":"2024","unstructured":"Zhaojian W, et al. Trends and off-label utilization of antipsychotics in children and adolescents from 2016 to 2021 in china: a real-world study. Child Adolesc Psychiatry Ment Health. 2024;18(1):77.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"12","key":"7113_CR32","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00127-013-0702-2","volume":"48","author":"YC Hsu","year":"2013","unstructured":"Hsu YC, et al. Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan. Soc Psychiatry Psychiatr Epidemiol. 2013;48(12):1889\u201396.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"11","key":"7113_CR33","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/pds.4244","volume":"26","author":"KSJ Lao","year":"2017","unstructured":"Lao KSJ, et al. Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: general and vulnerable patient groups. Pharmacoepidemiol Drug Saf. 2017;26(11):1387\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"7113_CR34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","volume":"161","author":"CU Correll","year":"2004","unstructured":"Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414\u201325.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"7113_CR35","first-page":"124","volume":"19","author":"C Panagiotopoulos","year":"2010","unstructured":"Panagiotopoulos C, et al. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2010;19(2):124\u201337.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"issue":"5","key":"7113_CR36","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4103\/0253-7613.117720","volume":"45","author":"S Sarkar","year":"2013","unstructured":"Sarkar S, Grover S. Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis. Indian J Pharmacol. 2013;45(5):439\u201346.","journal-title":"Indian J Pharmacol"},{"key":"7113_CR37","doi-asserted-by":"publisher","first-page":"102742","DOI":"10.1016\/j.ajp.2021.102742","volume":"62","author":"J Wang","year":"2021","unstructured":"Wang J, et al. Patterns of antipsychotic prescriptions in patients with schizophrenia in china: A National survey. Asian J Psychiatr. 2021;62:102742.","journal-title":"Asian J Psychiatr"},{"issue":"10","key":"7113_CR38","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/j.jaac.2023.07.496","volume":"62","author":"J Nazirbage","year":"2023","unstructured":"Nazirbage J. 75.3 Clozapine: practical applications for the child and adolescent psychiatrist. J Am Acad Child Adolesc Psychiatry. 2023;62(10):S110.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2 Suppl","key":"7113_CR39","first-page":"1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1\u201356.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"7113_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-2007-970062","volume":"40","author":"YT Xiang","year":"2007","unstructured":"Xiang YT, et al. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry. 2007;40(2):47\u201352.","journal-title":"Pharmacopsychiatry"},{"key":"7113_CR41","unstructured":"Qiu H et al. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan. Aust N Z J Psychiatry, 2018: p. 4867418805559."},{"issue":"8","key":"7113_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/phar.1453","volume":"34","author":"SN Salda\u00f1a","year":"2014","unstructured":"Salda\u00f1a SN, et al. Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization. Pharmacotherapy. 2014;34(8):836\u201344.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"7113_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.chc.2019.08.017","volume":"29","author":"DI Driver","year":"2020","unstructured":"Driver DI, et al. Childhood-Onset schizophrenia and Early-onset schizophrenia spectrum disorders: an update. Child Adolesc Psychiatr Clin N Am. 2020;29(1):71\u201390.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"5","key":"7113_CR44","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/00004583-199406000-00002","volume":"33","author":"J McClellan","year":"1994","unstructured":"McClellan J, Werry J. Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1994;33(5):616\u201335.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"7113_CR45","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/ajhp\/zxab392","volume":"79","author":"J Loucks","year":"2022","unstructured":"Loucks J, et al. Proportion of days covered as a measure of medication adherence. Am J Health Syst Pharm. 2022;79(6):492\u20136.","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"7113_CR46","first-page":"117","volume":"92","author":"LA Anghel","year":"2019","unstructured":"Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117\u201322.","journal-title":"Med Pharm Rep"},{"issue":"4","key":"7113_CR47","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi K, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200\u201318.","journal-title":"Ther Adv Psychopharmacol"},{"key":"7113_CR48","doi-asserted-by":"crossref","unstructured":"Wang H et al. Persistence with and adherence to Paliperidone palmitate Once-Monthly injection for schizophrenia treatment in China and Japan. J Clin Psychiatry. 2021; 83(1).","DOI":"10.4088\/JCP.20m13850"},{"issue":"5","key":"7113_CR49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/YIC.0b013e328303ac75","volume":"23","author":"M Nose","year":"2008","unstructured":"Nose M, et al. Is the defined daily dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol. 2008;23(5):287\u201390.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"7113_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1756-5391.2012.01166.x","volume":"5","author":"L Zhang","year":"2012","unstructured":"Zhang L, et al. Applying children defined daily dose to assess appropriate dose in pediatrics. J Evid Based Med. 2012;5(1):2\u20135.","journal-title":"J Evid Based Med"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07113-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07113-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07113-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:08:44Z","timestamp":1751375324000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-07113-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7113"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07113-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yongjing Zhang, Tao Wu, Sijia Dong, and Hong Qiu are employees of Johnson and Johnson. Yongjing Zhang and Hong Qiu report stock ownership in Johnson and Johnson. Other authors declared no conflicts of interest to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"657"}}